EUVIMEDEUVIMED entdecken
Kohortenstudie

Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study

Chengyang Xu, Ai Guan, Lu Zhang, Zhuang Tian, Daobin Zhou, Kai Sun, Kaini Shen, Jian Li iD

Advances in Therapy · 2026

DOI: 10.1007/s12325-025-03474-3 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Advances in Therapy, 2026. Verfasst von Chengyang Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuy…. Hauptthemen laut MEDLINE: Amyloidosis, Liver, Immunoglobulin Light-chain Amyloidosis, Liver Diseases. Die Arbeit nennt 20 Literaturangaben. Gefördert von: National Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Hematologic response is well established in systemic light chain (AL) amyloidosis treatment, but hepatic response patterns remain unclear. This study explored hepatic response dynamics in hepatic-involved patients with AL amyloidosis who achieved hematologic partial response within 24 months post-treatment. METHODS: Using two- and four-level hepatic response criteria (two-level: hepatic organ response [hepatic OR], hepatic no response [hepatic NR]; four-level: hepatic complete response [hepaCR], hepatic very good partial response [hepaVGPR], hepatic partial response [hepaPR], hepatic no response [hepaNR]), responses were assessed at 3, 6, 12, and 24 months. RESULTS: Among 137 patients (median follow-up: 55.0 months), hepatic OR and ≥ hepaPR plateaued at 24 months, with hepatic OR achieved in 75.6% (65/86), hepaCR in 10.5% (9/86), hepaVGPR in 16.3% (14/86), and hepaPR in 38.4% (33/86). The two-level hepatic response better predicted overall survival than the four-level criteria. Patients achieving hepatic OR within 24 months had significantly better prognosis than non-responders (log-rank p = 0.008; HR, 2.782; 95% CI, 1.260-6.141), with no impact from response speed. Hematologic complete response (CRH) at 3 months predicted higher likelihood of 24-month hepatic OR (OR 2.571, 95% CI, 1.387-4.767, p = 0.003). CONCLUSION: The study highlights the importance of monitoring hepatic response dynamics, identifying 3-month CRH and 24-month hepatic OR as key treatment milestones. A graphical abstract is also available with this article. For patients with systemic AL amyloidosis where the liver is affected, doctors closely monitor how well treatment works by tracking improvements in blood tests, but the patterns of how the liver itself recovers have been less clear. This study found that in patients who already show a good blood response, liver improvement typically plateaus by 24 months, with most patients achieving a significant liver response. The research showed that simply assessing whether the liver has responded or not is a more powerful predictor of a patient’s long-term survival than using more complex grading systems. Crucially, patients whose livers responded within 24 months had a significantly better prognosis, and the speed of that response did not matter. Furthermore, achieving a complete response in the blood as early as 3 months after treatment was a strong indicator that the liver would later recover. This identifies these two milestones, a complete blood response at 3 months and a liver response by 24 months, as key goals for treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisLiverImmunoglobulin Light-chain AmyloidosisLiver DiseasesHumansFemaleMaleRetrospective StudiesMiddle AgedAgedPrognosisTreatment OutcomeBortezomibAged, 80 and over

Stichwörter der Autor:innen

ALPAmyloidosisHepatic response dynamics

Substanzen

Bortezomib

Autor:innen und Institutionen

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China.
  • Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Uni…
  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China.…
  • State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. lijian@pumch.cn.

ORCID-Profile: Jian Li

Förderung

  • National Natural Science Foundation of China
  • CAMS Innovation Fund for Medical Sciences
  • National High Level Hospital Clinical Research Funding
  • Beijing Physician Scientist Training Project
  • Fundamental Research Funds for the Central Universities, Peking Union Medical College

Zitieren

APA

Xu, C., Guan, A., Zhang, L., Tian, Z., Zhou, D., Sun, K., Shen, K., & Li, J. (2026). Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study. Advances in Therapy. https://doi.org/10.1007/s12325-025-03474-3

Vancouver

Xu C, Guan A, Zhang L, Tian Z, Zhou D, Sun K, et al. Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study. Advances in Therapy. 2026. doi:10.1007/s12325-025-03474-3

BibTeX
@article{Xu2026,
  author = {Xu, Chengyang and Guan, Ai and Zhang, Lu and Tian, Zhuang and Zhou, Daobin and Sun, Kai and Shen, Kaini and Li, Jian},
  title = {Hepatic Response Dynamics in Newly Diagnosed Patients with Light-chain Amyloidosis: A Retrospective Cohort Study},
  journal = {Advances in Therapy},
  year = {2026},
  doi = {10.1007/s12325-025-03474-3}
}
Kostenlos starten →